share_log

Bristol-Myers Squibb | PRE 14A: Preliminary proxy statements relating to merger or acquisition

Bristol-Myers Squibb | PRE 14A: Preliminary proxy statements relating to merger or acquisition

施贵宝 | PRE 14A:并购重组委托声明
美股SEC公告 ·  03/18 17:26

Moomoo AI 已提取核心信息

Bristol-Myers Squibb (BMS) announced the virtual 2024 Annual Meeting of Shareholders to be held on May 7, 2024. Shareholders of record as of March 14, 2024, are entitled to vote on several key proposals, including the election of 10 board directors, advisory vote on executive compensation, ratification of Deloitte & Touche LLP as the independent auditor, and an amendment to the Certificate of Incorporation for limited officer exculpation. Additionally, three shareholder proposals will be considered. The Board recommends votes for the election of directors, executive compensation, auditor ratification, and the charter amendment, but against all shareholder proposals. The meeting will also address the CEO transition, with Dr. Christopher Boerner succeeding Dr. Giovanni Caforio. BMS emphasizes the meeting's accessibility and the ability for shareholders to participate virtually.
Bristol-Myers Squibb (BMS) announced the virtual 2024 Annual Meeting of Shareholders to be held on May 7, 2024. Shareholders of record as of March 14, 2024, are entitled to vote on several key proposals, including the election of 10 board directors, advisory vote on executive compensation, ratification of Deloitte & Touche LLP as the independent auditor, and an amendment to the Certificate of Incorporation for limited officer exculpation. Additionally, three shareholder proposals will be considered. The Board recommends votes for the election of directors, executive compensation, auditor ratification, and the charter amendment, but against all shareholder proposals. The meeting will also address the CEO transition, with Dr. Christopher Boerner succeeding Dr. Giovanni Caforio. BMS emphasizes the meeting's accessibility and the ability for shareholders to participate virtually.
百时美施贵宝(BMS)宣布将于2024年5月7日举行虚拟的2024年年度股东大会。截至2024年3月14日,登记在册的股东有权对几项关键提案进行投票,包括选举10名董事会董事,关于高管薪酬的咨询投票,批准德勤会计师事务所作为独立审计师,以及对有限高管人员免职的公司注册证书修正案。此外,还将考虑三项股东提案。董事会建议对董事选举、高管薪酬、审计师批准和章程修正案进行投票,但反对所有股东提案。会议还将讨论首席执行官的过渡问题,克里斯托弗·博尔纳博士将接替乔瓦尼·卡福里奥博士。BMS强调会议的可访问性以及股东虚拟参与的能力。
百时美施贵宝(BMS)宣布将于2024年5月7日举行虚拟的2024年年度股东大会。截至2024年3月14日,登记在册的股东有权对几项关键提案进行投票,包括选举10名董事会董事,关于高管薪酬的咨询投票,批准德勤会计师事务所作为独立审计师,以及对有限高管人员免职的公司注册证书修正案。此外,还将考虑三项股东提案。董事会建议对董事选举、高管薪酬、审计师批准和章程修正案进行投票,但反对所有股东提案。会议还将讨论首席执行官的过渡问题,克里斯托弗·博尔纳博士将接替乔瓦尼·卡福里奥博士。BMS强调会议的可访问性以及股东虚拟参与的能力。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息